Age Related Macular Degeneration Market to Grow Positively at a Paltry CAGR During the Study Period (2020-2034), DelveInsight | Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Scien

Eylea, developed by Regeneron, is a medication used to treat wet age-related macular degeneration (wet-AMD) as well as diabetic eye disease and other retinal conditions. Administered through intravitreal injection, Eylea helps slow vision loss associated with these diseases. The drug is the brand name for aflibercept, which works by inhibiting vascular endothelial growth factor (VEGF), a protein that naturally occurs in the body and triggers angiogenesis.
DelveInsight's "Age Related Macular Degeneration - Market Insight, Epidemiology and Market Forecast - 2034 [https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report provides current treatment practices, emerging drugs, Age Related Macular Degeneration market share of the individual therapies, current and forecasted Age Related Macular Degeneration market size from 2020 to 2034 segmented by seven major markets. The report also offers current Age Related Macular Degeneration therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Age Related Macular Degeneration market.

Download sample pages of our report @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key highlights from the Age-Related Macular Degeneration Market report:

*
The Age-related Macular Degeneration (AMD) market across the seven major markets is divided into two segments: Dry AMD and Wet AMD. According to our analysis, the total AMD market size in 2021 was approximately USD 9,840 million, with expectations for continued growth through 2034.

*
In 2021, the market size for Dry AMD was estimated at approximately USD 1,377 million, while Wet AMD accounted for around USD 8,463 million. Both segments are projected to see significant growth by 2034, driven in part by an increasing diagnosed prevalent population of AMD.

*
The anticipated launch of new therapies is expected to further expand the market, particularly in Wet AMD. Emerging therapies such as OPT-302, KSI-301, RGX-314, AKST4290, and others have the potential to create a major positive shift in the Wet AMD market, contributing to substantial market growth in the coming years.

Age Related Macular Degeneration Overview

Age-related Macular Degeneration (AMD) is the leading cause of blindness among the elderly in developed countries. This eye disease primarily affects older individuals, causing progressive loss of central vision, which is essential for activities such as driving, reading, recognizing faces, and perceiving color. As AMD progresses, patients experience a significant deterioration in their ability to read, write, and recognize detail or color, severely impacting their quality of life. Although the precise mechanisms underlying AMD are not yet fully understood, recent advancements in genetic research have led to the identification of various genetic polymorphisms that show distinct associations with the disease.

AMD is characterized by the gradual degeneration of the macula, the central part of the retina, resulting in the loss of central vision. The disease can be classified into three stages based on clinical features: early, intermediate, and late AMD. These stages are identified by the presence of drusen, pigmentation abnormalities, atrophy of the retinal pigment epithelium (RPE), and exudative choroidal neovascularization (CNV).

AMD is also categorized into two types: dry (atrophic or non-neovascular) and wet (exudative or neovascular).

Request for a sample report: https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Age Related Macular Degeneration Epidemiological Insights

*
In 2021, the total prevalent cases of Age-related Macular Degeneration (AMD) across the 7MM were approximately 51,743,361, with an expected compound annual growth rate (CAGR) of 1.6% through 2034.

*
The US accounted for around 17,282,569 AMD prevalent cases in 2021. Among the EU-5 countries, Germany had the highest number of prevalent AMD cases, totaling 7,850,793, followed by France. In Japan, approximately 21% of the total prevalent AMD cases in the 7MM were reported in 2021.

*
In 2021, the total diagnosed AMD cases across the 7MM were approximately 38,807,521, with the highest number of diagnosed cases in the US. Type-specific analysis revealed approximately 3,880,752 cases of Wet-AMD and 34,926,768 cases of Dry-AMD in the same year. These numbers are projected to increase significantly by 2034.

*
The epidemiology model divides AMD cases (both Dry and Wet) into age groups: 50-59 years, 60-69 years, 70-79 years, and greater than or equal to 80 years. According to DelveInsight estimates, the total age-specific AMD cases are expected to rise throughout the forecast period from 2022 to 2034.

*
In the US, the diagnosed cases of Dry AMD by age group in 2021 were 2,175,435 for 50-59 years, 3,380,209 for 60-69 years, 3,495,783 for 70-79 years, and 2,614,307 for greater than or equal to 80 years. By stage, there were approximately 10,499,160 early and intermediate Dry AMD cases and 1,166,573 advanced cases (geographic atrophy associated with Dry AMD). These stage-specific cases are also expected to rise by 2034.

*
For geographic atrophy cases in the US, visual impairment was categorized as mild (349,972 cases), moderate to severe (583,287 cases), and those requiring surgery or classified as legally blind (233,315 cases) in 2021.

Age-related Macular Degeneration Marketed Drugs

*
Eylea (aflibercept): Regeneron Pharmaceuticals

Eylea developed by Regeneron is used to treat wet-AMD. It is also used to treat diabetic eye disease and other problems of the retina. It is injected into the eye to help slow vision loss from these diseases. Eylea is the brand name for the drug called aflibercept. VEGF, a naturally occurring protein in the body triggers angiogenesis, however, in wet-AMD it is associated with abnormal blood vessel growth which causes edema leading to vision loss. Eylea blocks the growth of abnormal blood vessels in the back of the eye.

At present Regeneron is conducting phase III trials to explore less frequent dosing intervals of Eylea. It is evaluating the drug for a higher dose of 8mg in wet-AMD patients after phase II trials met its primary endpoint.

*
Beovu (brolucizumab): Novartis

Beovu (brolucizumab) is the most clinically advanced humanized single-chain antibody fragment (scFv). Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation, and drug delivery characteristics.

Beovu is the first FDA-approved anti-VEGF to offer both greater fluid resolution versus aflibercept and the ability to maintain eligible wet AMD patients on a three-month dosing interval immediately after a three-month loading phase with uncompromised efficacy.

Download sample pages @ https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Age Related Macular Degeneration Market Outlook

Age-related Macular Degeneration (AMD) is a chronic, progressive, and debilitating disease affecting the central retina, making it the leading cause of irreversible blindness in both Western countries and the Asia-Pacific region. Currently, approximately 8.7% of the global population is affected by AMD. The wet form of the disease is responsible for over 90% of the severe central vision loss associated with AMD.

Wet AMD Market Outlook

The introduction of anti-VEGF (vascular endothelial growth factor) intravitreal injections has revolutionized the treatment of wet AMD, effectively blocking the underlying pathophysiological processes, restoring retinal morphology, and preserving its function. Over the years, anti-VEGF injections have become the standard of care for wet AMD, offering significantly better outcomes compared to previous treatments such as photodynamic therapy (PDT) and laser photocoagulation. Current therapies, including Lucentis (ranibizumab), Eylea (aflibercept), and Avastin (bevacizumab), have demonstrated strong efficacy in achieving rapid resolution of exudative signs in most patients. Additionally, Faricimab and Susvimo have been recently approved as new treatment options for wet AMD.

Dry AMD Market Outlook

Unlike wet AMD, the therapeutic landscape for dry AMD remains largely unmet, with no approved treatments available to slow the disease's progression. The pathophysiology of dry AMD is not fully understood, and the failure to achieve primary clinical outcomes in some trials may be more closely tied to the advanced stage of the disease, rather than a lack of targeting the appropriate mechanisms. DelveInsight's market analysis focuses specifically on pharmacological treatments and does not include lifestyle management or procedures for dry AMD. The market size forecast only considers the revenue generated from approved pharmacological therapies for dry AMD, underscoring the need for new, effective treatments to address this growing unmet need.

Promising Therapies in the Age Related Macular Degeneration Pipeline

*
Eylea (aflibercept)

*
Beovu (brolucizumab)

*
Lucentis (ranibizumab)

*
OPT-302

*
KSI-301

*
RGX-314

*
Danicopan (ALXN2040)

*
EG-301

*
And others

Leading Companies Working in the Age Related Macular Degeneration Market [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

*
Regeneron Pharmaceuticals

*
Novartis

*
Roche

*
Opthea Limited

*
Kodiak Sciences Inc.

*
Regenxbio

*
Alexion Pharmaceuticals

*
AstraZeneca

*
Evergreen Therapeutics

*
And others

Scope of the Age Related Macular Degeneration Market Report:

Study Period: 2020-2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]

Key Age Related Macular Degeneration Companies: Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., Regenxbio, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, and others

Key Age Related Macular Degeneration Pipeline Therapies: Eylea (aflibercept), Beovu (brolucizumab), Lucentis (ranibizumab), OPT-302, KSI-301, RGX-314, Danicopan (ALXN2040), EG-301, and others

Therapeutic Assessment: Age Related Macular Degeneration current marketed and emerging therapies

Age Related Macular Degeneration Market Dynamics: Age Related Macular Degeneration market drivers and barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Unmet Needs, KOL's views, Analyst's views, Age Related Macular Degeneration Market Access and Reimbursement

Table of Contents:

1. Age Related Macular Degeneration Market Key Insights

2. Age Related Macular Degeneration Market Report Introduction

3. Age Related Macular Degeneration Market Overview at a Glance

4. Age Related Macular Degeneration Market Executive Summary

5. Disease Background and Overview

6. Age Related Macular Degeneration Treatment and Management

7. Age Related Macular Degeneration Epidemiology and Patient Population

8. Patient Journey

9. Age Related Macular Degeneration Emerging Drugs

10. 7MM Age Related Macular Degeneration Market Analysis

11. Age Related Macular Degeneration Market Outlook

12. Potential of Current and Emerging Therapies

13. KOL Views

14. Age Related Macular Degeneration Market Drivers

15. Age Related Macular Degeneration Market Barriers

16. Unmet Needs

17. SWOT Analysis

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=age-related-macular-degeneration-market-to-grow-positively-at-a-paltry-cagr-during-the-study-period-20202034-delveinsight-regeneron-pharmaceuticals-novartis-roche-opthea-limited-kodiak-scien]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.